News

News

IMI project COMBINE launched

COMBINE will support the coordination of the Innovative Medicines Initiative (IMI) Antimicrobial Resistance (AMR) Accelerator Programme…

Researchers open up new antibiotic reservoir

For the first time, scientists from Jena succeeded to cultivate and functionally characterize a total of…

BEAM Alliance released memo on PULL incentives

A new EU report sees only slow progress in the fight against AMR. The BEAM Alliance…

AMR: ENABLE selects Mutabilis candidate

A drug combo breaking antibiotic resistance of Gram-negative priority pathogens has been selected under the ENABLE…

New players to step into the AMR field

Despite challenging markets new players are entering the field to advance drug development in the fight…

The AMR business (Part I)

Antibiotic developers struggle with uncertain market conditions, weak reimbursement schemes and low turnover once a drug…

BioVersys receives up to €8m from CARB-X

Swiss biotech company BioVersys AG has received a €8m grant by US-based non-profit organisation CARB-X to…

Polyphor presents AMR breaker

Swiss Polyphor AG and researchers from the University of Zurich have presented the mechanism of action…

IMI AMR Accelerator: Allow the few to make the most of their resources

In 2019, a new AMR accelerator kicked off under the aegis of the Innovative Medicines Initiative…

Procarta Biosystems receives CARB-X funding

UK–based biotech company Procarta Biosystems has been funded by CARB-X to develop a new class of…

India joins the Global AMR R&D hub

India has joined the Global AMR R&D Hub as a new Member. This expands the global…

Antibiotic resistance without use of antibiotics

Swiss researchers from Zurich and Basel have discovered that resistance in intestinal bacteria can spread even…

Public consultation on TPPs for diagnostics

WHO has published target product profiles for diagnostics against antibacterial resistance identified as priorities. Until 29th…

From Melinta Therapeutics to CARB-X

Erin Duffy, former CSO of US biotech company Melinta Therapeutics, replaces Karen Gallant as CARB-X‘s Chief…

Global AMR R&D Hub seeks for comments on Draft Collaboration Framework

To help guide the Global AMR R&D Hub’s collaborations a draft Collaboration Framework has been developed.…

CARB-X funds vaccines companies

CARB-X has recently funded several vaccines projects to fight AMR-related infections developed by US-based SutroVax and…

WHO publishes TPPs for needed antibacterial agents

The WHO has developed several draft target products profiles (TPPs) and is seeking feedback from AMR…

Nabriva receives FDA approval for novel antibiotic

Nabriva Therapeutics plc has got the go from the FDA to market its pleuromutilin antibiotic Xenleta…

New IMI project ‘GNA Now’ kicks off battle against antimicrobial resistance

Evotec SE and Lygature announced their cooperation in a new initiative for the development of novel…

The AMR Centre set for partnership with Shionogi for new superbug therapy

The AMR Centre Ltd has today announced a landmark agreement with the Japanese pharma company Shionogi…

BARDA provides US$20.7m for novel antibiotic to fight resistant infections

HHS’s Biomedical Advanced Research and Development Authority, or BARDA, will provide up to $20.7 million over…

Novo Holdings REPAIR Impact Fund Invests US$10m in Curza and Spero

Today, the Novo Holdings REPAIR Impact Fund announced a USD 5.25 million investment in Curza, a…

Partnership in pursuit of new antibiotics class

A new collaboration aims to the urgent fight against antimicrobial resistant bacteria. Lyon-headquartered biotech Nosopharm has…

FIND signs US14.5m grant for NGS TB diagnosis

FIND signs US$14.5 million grant with Unitaid to evaluate next-generation sequencing for rapid, affordable diagnosis of…

GARDP wants five AMR breakers by 2025

GARDP has calls up the global community to develop five new treatments that break antimicrobial resistance…

BioVersys announces a €6.92m funding of its TRIC-TB project by IMI2 JU

BioVersys has been awarded EUR 6.92 Million funding for TRIC-TB from the Innovative Medicines Initiative 2…

CARB-X launches new Funding Rounds

In late April, CARB-X announced its 2019 rounds of funding to support the development of antibiotics,…

REPAIR Impact Fund opens AMR investment proposal round

The REPAIR Impact Fund has opened its second investment proposal round to European life science companies…

BEAM Alliance released position paper on PUSH incentives

BEAM Alliance has released a new position paper on PUSH Incentives called ‘Supporting financial investments on…

AMR Centre receives funding to fight antimicrobial resistance

The AMR Centre has received £2.3 million to support the expansion of its pipeline of new…

Bacteria may travel thousands of miles through the air globally

Bacteria may travel thousands of miles through the air worldwide instead of hitching rides with people…

AMR Conference in Berlin: Call for better incentives

More than 330 experts joined the 2-day AMR Conference 2019 in Berlin. They called for rapid…

Press release | AMR conference: Global experts discuss AMR market and financing challenges

More than 330 international experts will come together in Berlin to discuss the most pressing challenges…

Interview with Kevin Outterson, CARB-X: Why expansion is necessary

We spoke with Kevin Outterson, Executive Director of CARB-X and speaker at AMR Conference 2019, about…

CARB-X expands reach in Europe

CARB-X has expanded its reach by adding six partners from Germany, Switzerland, Denmark and India to…

How research in UK is progressing to tackle AMR

In Mid-February, the UKRI Cross-Council AMR Initiative hosted a parliamentary panel highlighted the importance of research…

Evotec and Helmholtz Centre joining platforms for novel antibiotics

German stakeholders Evotec AG and the Helmholtz Centre for Infection Research (HZI) have joined platforms in…

Insects and their microbiomes are a new resource for novel antibiotics

US researchers have shown that insect-associated microbes provide their hosts with protection against infections, suggesting that…

JPI AMR dashboard shows public investments in AMR

According to the newly published JPI AMR Research Funding Dashboard, the 22 member countries invested around…

Pull incentives to happen during 116th congress?

US stakeholders active in AMR have sent a letter to US congress representatives urging the need…

Recida Therapeutics receives CARB-X funding

CARB-X funds US-company Recida Therapeutics to accelerate further development of the LpxC program to treat gram-negative…

NIAID updates AMR strategy

NIAID is updating its antimicrobial resistance program and is seeking public input into strategic approaches. In…

CARB-X backs Swiss Polyphor

CARB-X is providing funding for the further development of Polyphor’s new class of Outer Membrane Protein…

Start-up Amprologix receives £1.2million government funding

The British start-up Amprologix secured government funding to make its epidermicin NI01 antibiotic ready for the…

Draft resolution on AMR prepared for next WHA

The executive board of the WHO’s World Health Assembly has agreed on a draft solution on…

UN IACG released draft recommendations

The UN IACG has now released its draft recommendations. Until Februar 19, all stakeholders are invited…

Antibiotic-resistant gene NDM-1 discovered in the Arctic

British researchers have discovered the antibiotic-resistant gene NDM-1 in arctic soils, far away of human presence.…

WHO calls for data to establish pre-clinical pipeline overview

The World Health Organization has published a first call to establish a pre-clinical pipeline overview in…

UK launches new payment model for antimicrobials

In order to incentivise drug companies to re-enter development of antibiotics, the UK government announced it…

FDA finalizes guidance on development of AST

FDA has finalized its guidance on how to coordinate development of antimicrobials and ASTs. In February,…

BARDA seeks input on DRIVe Venture initiative

US agency BARDA is pushing forward its DRIVe Venture initiative. It now seeks feedback on this…

Novo Holdings funds companies with €18m

Novo Holdings has invested €18m from its €135m REPAIR Impact Fund into four companies and appointed…

Public consultation for revised EMA guidelines

EMA has published a revised guideline that aims to strengthen the development of new antibacterial medicines.…

WHO: AMR among key health threats

The World Health Organization has published the ten threats to global health that merit special attention…

CDC will update AMR report in 2019

The Centers for Disease Control and Prevention (CDC) are working towards an update of their Antimicrobial…

New phase 3 clinical trial results for a MDR-TB drug

A phase 3 trial of delamanid, a newer oral drug for treating multidrug-resistant tuberculosis (MDR-TB), found…

Grand Challenges Meeting: Videos available

During the Grand Challenges meeting of Bill and Melinda Gates Foundation in October 2018, there was…

New drug resistant bacteria species found in China

In China, two new bacteria species have been found in patients’s blood. They were found during…

Forbes: Why animal health startups should be thinking about antibiotics

An article in Forbes explores, why more startups in animal health should develop novel antibiotics and…

Two new species of antibiotic resistant bacteria found in China

Researchers of Sichuan University, China, report that they have discovered two new species of resistant bacteria…

Ares Genetics advances AI-powered antibiotic resistance test

Curetis’ subsidiary Ares Genetics advances AI-powered antibiotic resistance test within a new project co-funded by Vienna…

CDC awards US$15m to find solutions for AMR

The US Centers for Disease Control & Prevention (CDC) has awarded more than US$15m for innovative…

France and Germany launch joint call for AMR projects

The French and German research ministries are launching their first joint call for projects on antimicrobial…

Forge Therapeutics receives 2nd CARB-X award

Forge Therapeutics, Inc., a biotechnology company developing novel medicines targeting metalloenzymes, announced that it has received…

Novartis provides data to SPARK

Novartis is donating data from its abandoned antibiotic research programmes on Pew’s open-access SPARK. Launched in…